Drug reference
beclomethasone dipropionate
Inhaled corticosteroid · Anti-asthmatic, Anti-inflammatory (pulmonary), Corticosteroid (inhaled), Anti-allergic rhinitis (nasal spray for ciclesonide prodrug usage noted, applicable here too for general ICS class info about nasal sprays later in the book likely not this chapter, but contextually for BDP, it's focused on pulmonary). I will stick to pulmonary categories directly supported by the text for BDP. The text explicitly mentions ciclesonide nasal spray. For BDP, it's
Inhaled corticosteroidAnti-asthmatic, Anti-inflammatory (pulmonary), Corticosteroid (inhaled), Anti-allergic rhinitis (nasal spray for ciclesonide prodrug usage noted, applicable here too for general ICS class info about nasal sprays later in the book likely not this chapter, but contextually for BDP, it's focused on pulmonary). I will stick to pulmonary categories directly supported by the text for BDP. The text explicitly mentions ciclesonide nasal spray. For BDP, it's
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
A
FDA category + note
Mechanism
Not yet extracted
Indications
Persistent asthma (when inhaled β2 agonists are required almost daily or the disease is not only episodic)Prophylaxis of asthmaPerennial rhinitis (intranasal spray)Variety of dermatological conditionsSevere inflammatory conditionsUnresponsive eczemaPsoriasis
Dosing
- Adult
- 100–200 µg BD, titrate dose upward every 3–5 days; max 400 µg QID by inhalation (for asthma). 50 µg in each nostril BD–TDS (intranasal spray for perennial rhinitis).
Pharmacokinetics
Bioavailability
Low systemic activity due to poor absorption and/or marked first-pass metabolism
Contraindications
- No role during an acute attack or in status asthmaticus
Side effects
Common
Hoarseness of voiceDysphoniaSore throatAsymptomatic or symptomatic oropharyngeal candidiasisThinning of epidermisDermal atrophyTelangiectasiaStriaeEasy bruisingHypopigmentationDelayed wound healingFungal and bacterial infections
Serious
- Mood changes (at doses > 600 µg/day)
- Osteoporosis (at doses > 600 µg/day)
- Growth retardation in children (at doses > 600 µg/day)
- Bruising (at doses > 600 µg/day)
- Petechiae (at doses > 600 µg/day)
- Hyperglycaemia (at doses > 600 µg/day)
- Pituitary-adrenal suppression (at doses > 600 µg/day)
- Adrenal crisis
- Adrenal pituitary suppression (with large, repeated amounts)
- Cushing’s syndrome (rarely)
Pregnancy & lactation
Pregnancy
A
Related guidelines
Ask House about beclomethasone dipropionate
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: KD Tripathi 7e, Goodman & Gilman 14e·Verified: 2026-05-10 · House clinical team